Zydus Lifesciences has launched a real-world data registry trial to determine the benefits of its liver drug, Saroglitazar Magnesium, on pa...

Consolidated total revenue from operations of the company stood at Rs 3,784.8 crore for the quarter under consideration. It was Rs 3,658.9 ...

Consolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...

Orphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or ch...

Zydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, includ...

Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...

Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug c...

NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...

This development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies.

"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...